Abstract
Although the role of serine/threonine protein kinase C (PKC) in malignant transformation is known from decades, an anti-PKC based approach in cancer therapy was hampered for the difficulties in developing pharmacological compounds able to selectively inhibit specific PKC isoforms. In this review, the role of PKC-η and PKC-δ in promoting and counteracting tumor progression in different types of cancer, respectively, will be discussed in relationship with promising therapeutic perspectives based either on small molecule inhibitors or on natural compounds. Among a miriad of molecules able to modulate PKC activity, we will focus on the role of the enzastaurin and briostatin-1, which already entered clinical trials for several human cancers.
Keywords: PKC, apoptosis, differentiation, tumorigenesis
Mini-Reviews in Medicinal Chemistry
Title: Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Volume: 9 Issue: 4
Author(s): A. Gonelli, C. Mischiati, R. Guerrini, R. Voltan, S. Salvadori and G. Zauli
Affiliation:
Keywords: PKC, apoptosis, differentiation, tumorigenesis
Abstract: Although the role of serine/threonine protein kinase C (PKC) in malignant transformation is known from decades, an anti-PKC based approach in cancer therapy was hampered for the difficulties in developing pharmacological compounds able to selectively inhibit specific PKC isoforms. In this review, the role of PKC-η and PKC-δ in promoting and counteracting tumor progression in different types of cancer, respectively, will be discussed in relationship with promising therapeutic perspectives based either on small molecule inhibitors or on natural compounds. Among a miriad of molecules able to modulate PKC activity, we will focus on the role of the enzastaurin and briostatin-1, which already entered clinical trials for several human cancers.
Export Options
About this article
Cite this article as:
Gonelli A., Mischiati C., Guerrini R., Voltan R., Salvadori S. and Zauli G., Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents, Mini-Reviews in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/138955709787847967
DOI https://dx.doi.org/10.2174/138955709787847967 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Noble metal-dithiocarbamates precious allies in the fight against cancer
Mini-Reviews in Medicinal Chemistry Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines
Current Molecular Medicine mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets In Vivo Roles of CDC25 Phosphatases: Biological Insight into the Anti-Cancer Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets Foreword:
Current Pharmaceutical Design Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Therapeutic Potential of Natural Compounds that Regulate the Activity of Protein Kinase C
Current Medicinal Chemistry CD133+ Glioblastoma Stem-Like Cells Induce Vascular Mimicry in Vivo
Current Neurovascular Research The Mediterranean Diet and Gastrointestinal Cancers Risk
Recent Patents on Food, Nutrition & Agriculture Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry DNA Instability at Chromosomal Fragile Sites in Cancer
Current Genomics Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Current Medicinal Chemistry Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design NMR-based Drug Development and Improvement Against Malignant Melanoma – Implications for the MIA Protein Family
Current Medicinal Chemistry Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer
Current Medicinal Chemistry Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors
Current Drug Metabolism